Results 241 to 250 of about 18,423,630 (320)
British Journal of Clinical Pharmacology, EarlyView.Aims The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs. those with normal renal function. Methods Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) not on dialysis were ...
Chandrali S. Bhattacharya +10 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Deprescribing is complex because it involves patients' health, values, and preferences. The World Health Organization and Canadian Medication Appropriateness and Deprescribing Network have recommended that deprescribing be integrated into health curricula, prompting the need for further understanding about deprescribing education.
Brian J. Chow +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims The incidence of postmenopausal bleeding (PMB) has been increasing over the past years. Little is known about the risk of PMB after COVID‐19 vaccination. Our study aimed to investigate this based on routine general practitioner (GP) healthcare data from the Netherlands.
Rana Jajou +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Pharmacogenomics enables personalization of drug therapy improving effectiveness and/or safety. Dihydropyrimidine dehydrogenase [DPYD] testing prior to fluoropyrimidine chemotherapy was commissioned by NHS England in response to an update from the Medicines and Healthcare products Regulatory Agency.
Nisha Shaunak +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Patients with severe mental disorder and diabetes may be exposed to inappropriate polypharmacy increasing the risk of side effects and drug interactions. Although medication reviews may facilitate short‐term deprescribing, they are not known to affect clinical outcomes.
Johan Frederik Mebus Meyer Christensen +2 more
wiley +1 more source
Appraising the visibility, relevance and impacts of clinical pharmacology
British Journal of Clinical Pharmacology, EarlyView.Aims Clinical pharmacology (CP) used to be a strong medical and scientific field, but during the last three decades it seems to have lost some of its appeal. We reviewed the visibility, relevance and impact of CP and clinical pharmacologists across the globe and suggest ways to strengthen the discipline to address future pharmacotherapeutic challenges.
Serge Cremers +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims The aim of this study was to create a Turkish version of the Ascertaining Barriers to Compliance (ABC) taxonomy for medication adherence. Methods A systematic literature search was conducted, followed by a national Delphi study using suggested methods of the International Society for Medication Adherence for translation of the ABC taxonomy for ...
Cansu Goncuoglu +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims To identify, evaluate and summarize all published literature that investigated manipulations to pharmaceutical dosage forms of psychotropic medications that could be used for the purposes of tapering. Methods A systematic literature review was carried out of the available published literature on manipulations performed to psychotropic medications ...
Denis O'Brien +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt +7 more
wiley +1 more source